cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein–cyclophilin A interactions. *J Virol* 1995; **69**: 2451–2461.
30. Rosenwirth B, Billich A, Datema R, *et al.* Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. *Antimicrob Agents Chemother* 1994; **38**: 1763–1772.
31. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. *Biochem Biophys Res Commun* 2006; **343**: 879–884.
32. Ishii N, Watashi K, Hishiki T, *et al.* Diverse effects of cyclosporine on hepatitis C virus strain replication. *J Virol* 2006; **80**: 4510–4520.
33. Firpi RJ, Zhu H, Morelli G, *et al.* Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. *Liver Transpl* 2006; **12**: 51–57.
34. Henry SD, Metselaar HJ, Lonsdale RC, *et al.* Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. *Gastroenterology 2006;* **131**: 1452–1462.
35. Ma S, Boerner JE, TiongYip C, *et al.* NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. *Antimicrob Agents Chemother* 2006; **50**: 2976–2982.
36. Nakagawa M, Sakamoto N, Enomoto N, *et al.* Specific inhibition of hepatitis C virus replication by cyclosporin A. *Biochem Biophys Res Commun* 2004; **313**: 42–47.
37. Paeshuyse J, Kaul A, De Clercq E, *et al.* The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. *Hepatology* 2006; **43**: 761–770.
38. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. *J Gastroenterol* 2003; **38**: 567–572.
39. Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. *Transplantation* 2006; **82**: 579–580.

DOI: 10.1002/rmv

ELSEVIER

Journal of Hepatology 46 (2007) 26–36

Journal of Hepatology

www.elsevier.com/locate/jhep

Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes

Hussein H. Aly[1,2,3], Koichi Watashi[2], Makoto Hijikata[2], Hiroyasu Kaneko[2], Yasutugu Takada[1], Hiroto Egawa[1], Shinji Uemoto[1], Kunitada Shimotohno[2,*]

[1]*Graduate School of Medicine, Department of Transplant Surgery, Kyoto University Hospital, Kyoto, Japan*
[2]*Laboratory of Human Tumor Viruses, Institute of Virus Research, Kyoto University, Japan*
[3]*Hepatology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt*

See Editorial, pages 1–5

***Background/Aims*: The development of an efficient in vitro infection system for HCV is important in order to develop new anti-HCV strategy. Only Huh7 hepatocyte cell lines were shown to be infected with JFH-1 fulminant HCV-2a strain and its chimeras. Here we aimed to establish a primary hepatocyte cell line that could be infected by HCV particles from patients' sera.**

***Methods*: We transduced primary human hepatocytes with human telomerase reverse transcriptase together with human papilloma virus 18/E6E7 (HPV18/E6E7) genes or simian virus large T gene (SV40 T) to immortalize cells. We also established the HPV18/E6E7-immortalized hepatocytes in which interferon regulatory factor-7 was inactivated. Finally we analyzed HCV infectivity in these cells.**

***Results*: Even after prolonged culture HPV18/E6E7-immortalized hepatocytes exhibited hepatocyte functions and marker expression and were more prone to HCV infection than SV40 T-immortalized hepatocytes. The susceptibility of HPV18/E6E7-immortalized hepatocytes to HCV infection was further improved, in particular, by impairing signaling through interferon regulatory factor-7.**

***Conclusions*: HPV18/E6E7-immortalized hepatocytes are useful for the analysis of HCV infection, anti-HCV innate immune response, and screening of antiviral agents with a variety of HCV strains.**

Keywords: **Immortalization; Primary hepatocytes; HCV infection; IRF-7; IRF-3; HPV18/E6E7; Innate immune response**

1. Introduction

Infection with Hepatitis C virus (HCV) is a serious problem worldwide since 3% of the world's population is chronically infected [1]. Chronic HCV may lead to liver cirrhosis and hepatocellular carcinoma. Current standard therapy utilizes the combination of pegylated interferon-α and ribavirin, which results in a sustained response in only 30–60% of patients [2–5]. Many patients, however, do not qualify for or tolerate standard therapy [6]. Thus, it is important to develop an efficient in vitro infection system for HCV to facilitate the discovery of new anti-HCV strategies. Only Huh7 cell line is permissive for replication, infection and release of the fulminant hepatitis-derived HCV-2a (JFH-1) strain and its chimeric derivatives [7–9]. No other hepatocyte cell lines are able to support HCV replication efficiently.

Received 5 June 2006; received in revised form 24 July 2006; accepted 1 August 2006; available online 30 October 2006

* Corresponding author. Tel.: +81 75 751 4000; fax: +81 75 751 3998.
E-mail address: kshimoto@virus.kyoto-u.ac.jp (K. Shimotohno).

0168-8278/$32.00
doi:10.1016/j.jhep.2006.08.018

Normal human hepatocytes are the ideal system in which to study HCV infectivity. When cultured in vitro, however, they proliferate poorly and divide only a few times [10]. Continuous proliferation could be achieved however by introducing oncogenes, such as Simian virus large tumor antigen (SV40 T) [11]. This often resulted in tumor development [12] together with numerical (aneuploidy) and structural (aberrations) chromosome abnormalities [13]. The human papilloma virus E6E7 genes (HPV/E6E7) immortalized multiple cell types that were phenotypically and functionally similar to the parental cells [14–20]. As yet, no human hepatocytes have been immortalized with HPV18/E6E7.

We established a human primary non-neoplastic hepatocyte cell line transduced with the HPV18/E6E7 that retained primary hepatocyte characteristics even after prolonged culture, and were more prone to HCV infection than those cells immortalized with SV40 T antigen. We further improved the susceptibility of HPV18/E6E7-immortalized hepatocytes to HCV infectivity by impairing interferon regulatory factor-7 (IRF-7) expression. These cells are useful to assay infectivity of HCV strains other than JFH-1, HCV replication, innate immune system engagement of HCV, and screening of anti-HCV agents. This infection system using non-neoplastic cells also suggested that IRF-7 plays an important role in eliminating HCV infection.

2. Materials and methods

2.1. Cell cultures

We obtained the approval of the Ethical Committee of Kyoto University for the use of human hepatocytes and sera obtained from HCV-positive patients. Informed consent was obtained from both the hepatocyte donor and HCV-positive patients. Primary hepatocytes (P.H.) were cultured as described [21]. HeLa, 293, Huh-7.5, and PH5CH8 cells were cultured as previously described [22]. For three-dimensional (3D) cultures, Mebiol Gel (Mebiol Inc.) was prepared according to the manufacturer's instructions.

2.2. Plasmids construction

The SV40 T, hTERT and HPV/E6E7 fragments from pAct-SVT, PCX4neo/hTERT, and pLXSN-E6E7 plasmids were inserted into pCSII-EF-RFA plasmid creating the pCSII-EF-SVT, pCSII-EF-hTERT, and pCSII-EF-E6E7 plasmids, respectively. The full-length IRF-3 and IRF-7 genes were cloned by RT-PCR using total RNA isolated from 293 cells as a template and were inserted into pcDNA3 vector. Dominant-negative forms of IRF-3 (DNIRF-3) and IRF-7 (DNIRF-7) were constructed by PCR amplification of the coding region for amino acid residues 108–427 of IRF-3 and 237-514 of IRF-7, respectively. The amplified IRF-3 fragment was cloned into pcDNA3 in frame with a FLAG epitope tag generating pcFLAG-DNIRF-3. The amplified IRF-7 fragment was cloned into pLXSH in frame with HA epitope tag generating pLXSH-HA-DNIRF-7. The pIFNβ promoter-luc and pIFNα promoter-luc plasmids were gifts from Dr. Taniguchi of the Tokyo University. The psiRNA-hIRF-3 and psiRNA-hIRF-7 plasmids were purchased from Invivogen (USA).

2.3. Immunoblot analysis

Immunoblot analysis was performed as described previously [22]. We used anti-SV40 T (Santa Cruz), anti-HPV18/E7 (Santa Cruz), anti-tubulin (Sigma), anti-FLAG (Sigma), and anti-HA (Sigma) antibodies.

2.4. Transfection, small interfering RNA silencing and luciferase assays

Transfection of plasmid DNA was performed using Effectene transfection reagent (Qiagen) as recommended by the manufacturer. The pLXSH-HA-DNIRF-7 plasmid was transfected into the HuS-E/2 clone; transfectants were selected in 100 μg/ml hygromycin B (Gibco). The psiRNA-hIRF-3 and psiRNA-hIRF-7 plasmids were separately transfected into HuS-E/2 cells followed by Zeocin (250 μg/ml) selection. After two weeks of continuous selection, cells were infected with HCV. Luciferase assays were conducted as previously described [22]. The results are presented as relative light units (RLU) normalized to the total content of protein in the cell lysates.

2.5. Reverse transcriptase polymerase chain reaction (RT-PCR) and real-time RT-PCR

Using 250 ng of total RNA as a template, we performed RT-PCR with a one-step RNA PCR kit (Takara) according to the manufacturer's instructions. The primer sets and reaction conditions used are detailed in Table 1. To measure HCV-RNA titers by real-time RT-PCR, we collected RNA from infected wells. Five hundred nanograms of total cellular RNA was analyzed for the quantity of HCV-RNA as previously described [23].

2.6. HCV infection experiment

HCV infection experiment from serum was done as mentioned before [22]. HCV-infected-serums were titrated and 1×10^5 HCV-RNA copies/ml were used for each infection experiment. Concentrated culture medium for HCV/JFH1-producing cells was prepared as previously described [7]. HCV titer in the concentrated medium was measured, adjusted and added to the cells as mentioned above.

2.7. Blocking of HCV infectivity by anti-CD81

Inhibition of HCV infectivity was performed by blocking CD81 as previously described [7].

3. Results

3.1. Establishment of immortalized primary human hepatocytes

Primary hepatocytes were isolated from liver tissue obtained from a 9-year-old male patient with Primary Hyperoxaluria who had undergone liver transplantation. Hepatocytes were left unmanipulated or transduced with CSII-EF-hTERT alone or in combination with CSII-EF-SVT or CSII-EF-E6E7 to enhance the efficiency of immortalization. After six weeks only cells transduced by the combination of hTERT and either LT or HPV18/E6E7 continued to proliferate. Initially appearing colonies with a growth advantage were picked up and expanded. SV40 T-immortalized cell clones were named HuS-T cells and given numbers from 1 to 7,

Table 1
Primer sequences and RT-PCR parameters

Genes	Primer sequence 5′–3′	PCR parameters[a]
HGF	F: AGGAGCCAGCCTGAATGATGA R: CCCTCTGATGTCCCAAGATTAGC	95, 56, 72 1 min, 45 s, 1 min
TGFα	F: ATGGTCCCCTCGGCTGGA R: GGCCTGCTTCTTCTGGCTGGCA	95, 59, 72 45 s, 30 s, 1 min
TGFβ1	F: GCCCTGGACACCAACTATTGCT R: AGGCTCCAAATGTAGGGGCAGG	95, 58, 72 45 s, 30 s, 1 min
TGFβ2	F: GATTTCCATCTACAAGACCACGAGGGACTTGC R: CAGCATCAGTTACATCGAAGGAGAGCCATTCG	95, 58, 72 45 s, 30 s, 1 min
HGFR	F: TGGTCCTTGGCGTCGTCCTC R: CTCATCATCAGCGTTATCTTC	95, 54, 72 30 s, 45 s, 1 min
EGFR	F: CTACCACCACTCTTTGAACTGGACCAAGG R: TCTATGCTCTCACCCCGTTCCAAGTATCG	95, 58, 72 45 s, 30 s, 1 min
TGFβ1R	F: CGTGCTGACATCTATGCAAT R: AGCTGCTCCATTGGCATAC	95 s, 54, 72 30 s, 45 s, 1 min
TGFβ2R	F: TGCACATCGTCCTGTGGAC R: GTCTCAAACTGCTCTGAAGTGTTC	95, 58, 72 45 s, 30 s, 1 min
FGFR	F: ATGTGGAGCTGGAAGTGCCTC R: GGTGTTATCTGTTTCTTTCTCC	95, 54, 72 30 s, 45 s, 1 min
IGF-1R	F: ACCCGGAGTACTTCAGCGCT R: CACAGAAGCTTCGTTGAGAA	95, 54, 72 30 s, 45 s, 1 min
HNF1α	F: GTGTCTACAACTGGTTTGCC R: TGTAGACACTGTCACTAAGG	95, 52, 72 45 s, 30 s, 1 min
HNF1β	F: GAAACAATGAGATCACTTCCTCC R: CTTTGTGCAATTGCCATGACTCC	95, 52, 72 1 m, 45 s, 1 min
HNF3β	F: CACCCTACGCCTTAACCAC R: GGTAGTAGGAGGTATCTGCGG	95, 56, 72 1 m, 45 s, 1 min
HNF4	F: CTGCTCGGAGCCACAAAGAGATCCATG R: ATCATCTGCCACGTGATGCTCTGCA	95, 58, 72 45 s, 30 s, 1 min
Albumin	F: AGTTTGCAGAAGTTTCCAAGTTAGTG R: AGGTCCGCCCTGTCATCAG	95, 55, 72 45 s, 30 s, 1 min
Apolipoprotein-a	F:AGGCTCGGCATTTCTGGCAG R: TATCCCAGAACTCCTGGGTC	95, 55, 72 45 s, 30 s, 1 min
HTF	F: TCGCTACAGCCTTTGCAATG R: TTGAGGGTACGGAGGAGTTCC	95, 55, 72 45 s, 30 s, 1 min
E-cadherin	F: TCCATTTCTTGGTCTACGCC R: TTTGTCCTACCGACTTCCAC	95, 55, 72 45 s, 30 s, 1 min
CYP 1B1	F: CACCAAGGCTGAGACAGTGA R: GCCAGGTAAACTCCAAGCAC	94, 57, 72 30 s, 30 s, 1 min
CYP 2C9	F: GGACAGAGACGACAAGCACA R: TGGTGGGGAGAAGGTCAAT	94, 57, 72 30 s, 30 s, 1 min
CYP 2B	F: GGCACACAGCCAAGTTTACA R: CCAGCAAAGAAGAGCGAGAG	94, 57, 72 30 s, 30 s, 1 min
CYP 3A4	F: TGTGCCTGAGAACACCAGAG R: GCAGAGGAGCCAAATCTACC	94, 57, 72 30 s, 30 s, 1 min
CYP 2E1	F: CCGCAAGCATTTTGACTACA R: GCTCCTTCACCCTTTCAGAC	94, 57, 72 30 s, 30 s, 1 min
CYP 1A1	F: AGGCTTTTACATCCCCAAGG R: GCAATGGTCTCACCGATACA	94, 57, 72 30 s, 30 s, 1 min
GAPDH	F: CCATGGAGAAGGCTGGGG R: CAAAGTTGTCATGGATGACC	95, 8, 72 45 s, 30 s, 1 min

Table 1 (*continued*)

Genes	Primer sequence 5′–3′	PCR parameters[a]
CD81	F: CTCAACTGTTGTGGCTCCAAC R: CCAATGAGGTACAGCTTCCC	95, 55, 72 45 s, 30 s, 1 min
TLR3	F: GATCTGTCTCATAATGGCTTG R: GACAGATTCCGAATGCTTGTG	95, 55, 72 45 s, 30 s, 1 min
TLR7	F: CCAGACATCTCCCCAGCGTC R: GGCAAAACAGTAGGGACGGC	95, 55, 72 45 s, 30 s, 1 min
TLR8	F: CTGTGAGTTATGCGCCGAAG R: CGGGATTTCCGTTCTGGTGC	95, 55, 72 45 s, 30 s, 1 min
Myd88	F: GGTCTCCTCCACATCCTCCC R: CCAGCTTGGTAAGCAGCTCG	95, 55, 72 45 s, 30 s, 1 min
IRF3	F: GAACCCCAAAGCCACGGATC R: CCTCCCGGGAACATATGCAC	95, 55, 72 45 s, 30 s, 1 min
IRF7	F: GTGCTGTTCGGAGAGTGGCTC R: CAGCCCAGGCCTTGAAGATG	95, 55, 72 45 s, 30 s, 1 min

CYP, cytochrome P450; EGFR, epidermal growth factor receptor; F, forward primer; FGFR, fibroblast growth factor receptor; GAPDH, glyceraldehyde phosphate dehydrogenase; HGF, hepatocyte growth factor; HGFR, hepatocyte growth factor receptor; HNF, hepatocyte nuclear factor; HTF, human transferrin; IGF-1R, insulin-like growth factor-type I receptor; IRF, interferon regulatory factor; R, reverse primer; TGF, transforming growth factor; TGFR, transforming growth factor receptor; TLR, toll like receptor.

[a] Temperatures are tabulated in the first lane in degrees celsius and the corresponding times in the second lane. Performing one-step RT-PCR, reverse transcription was carried out at 42 °C for 20 min with a pre-PCR denaturation at 95 °C for 10 min.



Fig. 1. (A) Immunoblot detection of SV40 T and HPV E7 expression in HuS-T/2 and HuS-E/2 cells, respectively. 293-FT and HeLa cells were used as positive controls for SV40 T and HPV E7 expression, respectively. The specific bands representing the targets are indicated. Detection of tubulin expression in all cells served as an internal control. (B) Human Telomerase Reverse Transcriptase (hTERT) expression was examined by RT-PCR in freshly isolated hepatocytes and the HuS-E/2 and HuS-T/2 cell lines. GAPDH expression was used as an internal control. The hTERT-specific bands are shown. (C) Morphological characteristics of HuS-E/2 and HuS-T/2 cells after two (panels 1 and 2) and 30 (panels 3 and 4) weeks in culture. [This figure appears in colour on the web.]

while the HPV18/E6E7-immortalized clones were named HuS-E cells and given numbers from 1 to 4. Expression of SV40 T and HPV E7 proteins was detected in the appropriate cells by immunoblot analysis (Fig. 1A). In both immortalized cell lines, expression of hTERT-mRNA was enhanced in comparison to non-transduced, freshly isolated hepatocytes as determined by RT-PCR (Fig. 1B). HuS-E cells were larger in size and exhibited slower growth than HuS-T cells (Fig. 1C).

3.2. Characterization of HuS-E and HuS-T immortalized hepatocytes

The HuS-E/2 and HuS-T/2 clones demonstrated the highest expression of hepatocyte-specific markers and transcription factors by RT-PCR (data not shown); these cells were used as representative for each group in this study. To address if HuS-E/2 and HuS-T/2 maintained similar characteristics as primary hepatocytes, they were both cultured continuously for 30 weeks and the expression profiles of a variety of growth factors (Fig. 2A), growth factor receptors (Fig. 2B), hepatocyte-specific nuclear factors (Fig. 2C), albumin, apolipoprotein-A1, transferrin (Fig. 2D), cytochrome p450 (CYP) genes (Fig. 2E), and GAPDH were compared with freshly isolated primary hepatocytes after isolation or two weeks of culture, Huh-7.5 cells, and 293 cells. After two weeks in culture, the expression of nearly all examined genes was similar between freshly isolated hepatocytes and the HuS-E/2 cell line. HuS-E/2 cells, however, exhibited higher expression of TGFβ2 (Fig. 2A), TGFβ2R, and HGFR (Fig. 2B) and lower expression of CYP 3A4 and 2C9 (Fig. 2E) in comparison to freshly isolated hepatocytes. Primary hepatocytes displayed reduced expression of TGFβ1 and TGFβ2 (Fig. 2A) and a loss of CYP1A1 expression (Fig. 2E) after two weeks of culture. HuS-E/2 cells exhibited higher expression of HGF (Fig. 2A), HGF receptor (Fig. 2B), HNF-4, (Fig. 2C), albumin, apolipoprotein-A1, HTF, and E-cadherin (Fig. 2D) in comparison to HuS-T/2 cells. Expression of CYP 3A4 (Fig. 2E) was lost from both HuS-T/2 and HuS-E/2 cells, while HuS-T/2 cells also lost the expression of HNF-1α (Fig. 2D), and CYPs 2B, 2E1 (Fig. 2E).



Fig. 2. Expression of the genes encoding growth factors (A), growth factor receptors (B), hepatocyte-specific nuclear factors (C), hepatocyte differentiation and functional markers (D), and CYP enzymes (E) in 293 cells, freshly isolated primary hepatocytes (P.H.), primary hepatocytes cultured for two weeks (Cult. P.H.), Huh-7.5 cells, and HuS-E/2 and HuS-T/2 cells cultured for two and 30 weeks were investigated by RT-PCR. The bands representing specific targets are indicated in the representative reactions.



Fig. 3. (A) The morphology of HuS-E/2 and HuS-T/2 cells in 3D culture. HuSE/2 and HuS-T/2 cells were cultured in Mebiol Gel in 12-well plates at a concentration of 5×10^5 cells/well. The microscopic characteristics of these cells after one week of 3D culture are shown. (B) The expressions of HNF4α, HNF1β, albumin, and apo-A by HuS-E/2 and HuS-T/2 cells in both flat and 3D cultures are detailed. After one week of culture of HuS-E/2 and HuS-T/2 cells in flat and 3D cultures, the expressions of HNF4α, HNF1β, albumin, and apo-A were measured by RT-PCR in 250 ng total RNA.

HuS-T/2 but not in HuS-E/2 cells showed a transformed-like character starting from the 13th week of culture. This was demonstrated by continuing proliferation after confluence, pile-up formations (Fig. 1C), and proliferating in serum-deprevied condition. However, HuS-E/2 cells did not show any transformed-like characters even after 30 weeks of culture.

3.3. The characteristics of HuS-E and HuS-T immortalized hepatocytes in 3D culture

After one week in 3D culture, HuS-E/2 (Fig. 3A, panels 1, 2, and 3) cells adopted a donut-shaped structure with a central pore, while HuS-T/2 cells (Fig. 3A, panels 4, 5, and 6) displayed irregular mass formations (similar to the growth pattern of Huh-7.5 cells in 3D culture (data not shown)). In 3D culture, while the expression of HNF4, HNF1β, and albumin was enhanced in HuS-E/2, it was decreased in HuS-T/2 cells (Fig. 3B).

3.4. HCV infection to HuS-E/2

We further assessed the HCV infectivity of HuS-E- and HuS-T-derived clones by infection with HCV-1b-infected serum. Of the three HuS-E clones examined, HuS-E/2 clone demonstrated the highest infectability with HCV genotype 1b in comparison to Huh-7.5, PH5CH8 (Fig. 4A), and HuS-T cells (data not shown), which were excluded from further experiments.

3.5. Anti-CD81 blocked HCV infectivity

CD81 is involved in the entry of HCV pseudoparticles [24] and in vitro-synthesized JFH-1 [7]. To determine if authentic viral particles follow the same route of entry when infecting HuS-E/2 cells, we first examined the CD81 expression by RT-PCR. Both HuS-E/2 and HuS-T/2 cells expressed similar amounts of CD81 as freshly isolated hepatocytes and Huh-7.5 cells (Fig. 4B). Antibodies against CD81 reduced HCV infectivity of HuS-E/2 cells from the levels seen using a non-specific control antibody, confirming the importance of CD81 in HCV infectivity (Fig. 4C).

3.6. IFNα blocked HCV infectivity

We treated HuS-E/2 cells with HCV-containing serum. Cells were then cultured in fresh medium supplemented



Fig. 4. (A) Serum from an HCV patient was used to infect Huh-7.5 cells, PH5CH8 cells, and three HPV E6E7-immortalized clones (HuS-E/1-3) for 24 h. After washing three times in phosphate-buffered saline (PBS), cells were cultured in fresh medium. Cells were then harvested and lysed at the indicated time points. The quantity of HCV genome RNA per 500 ng total RNA was determined by real-time RT-PCR analysis. (B) HuS-E/2 and HuS-T/2 cells both expressed CD81. Expression of CD81 (upper panel) and GAPDH as an internal control (lower panel) in 293 cells, freshly isolated P.H., cultured P.H., and Huh-7.5, HuS-E/2, and HuS-T/2 cells was investigated by RT-PCR. (C) Anti-CD81 antibodies blocked HCV infectivity. HCV infection was performed as described in (A) with the addition of CD81-specific (black bar) or anti-tubulin antibodies (control, white bar). (D) IFNα inhibits HCV multiplication in HuS-E/2 cells infected with HCV-containing serum. HuS-E/2 cells were infected with HCV as described in (A). After washing three times with PBS, cells were cultured in fresh medium supplemented with (black bar) or without (white bar) 100 U/ml IFNα.

without or with 100 U/ml IFNα. The enhancement of the HCV-RNA genome titers on the fifth day (about 10-fold) was not observed in cells treated continuously with IFNα (Fig. 4D). This result suggests that IFNα inhibited HCV replication in infected HuS-E/2 cells.

3.7. The effect of blocking IRF-3 and IRF-7 signaling on HCV infectivity

Production of interferon-alpha (IFNα) and interferon-beta (IFNβ) limits viral replication and spread, providing one of the most effective innate antiviral responses [25]. Signaling through IRF-3 and IRF-7 plays important roles in the stimulation of IFN-α/β production [25]. To determined which molecules (IRF-3 or IRF-7) play an important role in modulation of the innate immune response against HCV infection in these cells, we first detected intrinsic expression of double-stranded RNA-stimulated Toll-like receptor (TLR) 3, the downstream effector IRF-3, single-stranded RNA-stimulated TLR7, and 8, and the downstream effectors MyD88 and IRF-7 by RT-PCR. TLR3 exhibited very low expression in freshly isolated hepatocytes, Huh-7.5, HuS-E/2, and HuS-T/2 cells, while TLR7, TLR8, MyD88, and IRF-7 were easily detectable in both freshly isolated and immortalized cell lines (Fig. 5A).

The abilities of DNIRF-3 and DNIRF-7 to inhibit IFNβ and IFNα production by HuS-E/2 cells infected with Sendai virus were confirmed using assays of IFNβ or IFNα promoter-driven luciferase reporters. DNIRF-3 exhibited strong inhibition of IFNβ production (Fig. 5B) and weaker inhibition of IFNα transcription (Fig. 5C), while DNIRF-7 strongly inhibited IFNα production (Fig. 5C) and only weakly inhibited IFNβ production (Fig. 5B).

We then assessed the inhibition of HCV infectivity by DNIRF-3 and DNIRF-7. Transient transfection with DNIRF-3, DNIRF-7, or an empty vector was performed prior to HCV infection. Using Effectene reagent, the efficiency of plasmid transfection into HuS-E/2 cells was approximately 70% (data not shown). While there was no significant effect of DNIRF-3 on HCV infectivity, DNIRF-7 demonstrated a marked increase in HCV titers on days 3 and 5 after infection in comparison to control cells (Fig. 5D). To confirm that the enhancement of HCV replication by DNIRF-7 is not mediated by the impairment of IRF-3 signaling by heterodimeric interactions between IRF-3 and DNIRF-7, we performed siRNA inhibition of IRF-3 and IRF-7. The reduction of IRF-3 and IRF-7 expression by siRNA was obvious by RT-PCR (Fig. 5E). siRNA-mediated suppression of either IRF-3 or IRF-7 inhibited IFNβ and IFNα production



Fig. 5. (A) We examined the expression of TLR3, TLR7, TLR8, MyD88, IRF-3, and IRF-7, as well as GAPDH as an internal control in freshly isolated primary hepatocytes and Huh-7.5, HuS-E/2, and HuS-T/2 cells was investigated by RT-PCR. (B and C) HuS-E/2 cells were cotransfected with pIFNβ-luc (B) or pIFNα-luc (C) with an expression plasmid encoding DNIRF-3, DNIRF-7, or the appropriate empty vector (pcDNA3 and PLXSH, respectively). Twenty-four hours later, cells were infected (black bar) with Sendai virus or mock-infected (white bar), then analyzed for luciferase activity after 12 h. (D) IRF-7, but not IRF-3, suppression enhanced HCV infectivity of HuS-E/2 cells. HuS-E/2 cells were transiently transfected with empty pcDNA3, DNIRF-3, empty pLXSH, or DNIRF-7 plasmids. Twenty-four hours later, serum from a patient with HCV was used to infect transfected cells for 24 h. After washing, cells were cultured in fresh medium. The cells were then harvested and lysed at the indicated time points. The quantity of HCV genome RNA per 500 ng total RNA was determined by real-time RT-PCR analysis. (E) IRF-3 and IRF-7 levels were suppressed by specific siRNAs. HuS-E/2 cells were transfected with control psiRNA-hTLR2, psiRNA-hIRF-3, or psiRNA-hIRF-7, then selected with Zeocin at 250 μg/ml. Two weeks later, cells were harvested and assessed for the expression of IRF-3 and IRF-7 by RT-PCR. (F and G) HuS-E/2 cells were transfected with control psiRNA-hTLR2, psiRNA-hIRF-3, or psiRNA-hIRF-7, followed by selection in Zeocin at 250 μg/ml. Two weeks later, cells were cotransfected with pIFNβ-luc (F) or pIFNα-luc (G). Twenty-four hours later, cells were infected (black bar) with Sendai virus or mock-infected (white bar), then analyzed for luciferase activity after 12 h. (H) Transfected cells were infected with serum from HCV patient; HCV infectivity was assessed as described above.

in HuS-E/2 cells infected with Sendai virus in patterns similar to the effects seen following DNIRF-3 and DNIRF-7 expression, respectively (Figs. 5F and G). Blockade of IRF-7 expression resulted in a significantly higher titer of HCV after infection, while IRF-3 down-regulation did not have any significant effect on HCV titers (Fig. 5H). The enhancement of IRF-7 silencing by siRNA improved the infectivity of HCV (data not shown). These results suggest that IRF-7 plays the major role in the innate immune response to HCV in HuS-E/2 cells.

3.8. Establishment of stable DNIRF-7 expressing clones derived from HuS-E/2 cells

Since DNIRF-7 enhanced HCV infectivity, we transduced the plasmid encoding DNIRF-7 and a hygromycin-B resistance gene, into HuS-E/2 cells. Following selection with hygromycin-B, we obtained the HuS-E7/DN22 and HuS-E7/DN24 clones. As detected by RT-PCR, both clones demonstrated similar expression levels of albumin, apolipoprotein-A1, and HNF4 as the parental HuS-E/2 cells (Fig. 6A). The HuS-E7/DN24 clone exhibited stronger expression of DNIRF-7 than the HuS-E7/DN22 clone by immunoblotting (Fig. 6B). The induction of IFNα in HuS-E7/DN24 in response to infection with an RNA virus (Sendai virus) was low in comparison to the parental HuS-E/2 and HuS-E7/DN22 clones, as detected by IFNα-luciferase reporter assay (Fig. 6C). HuS-E7/DN24 also exhibited a higher HCV infectability in comparison to parental HuS-E/2 cells and the HuS-E7/DN22 clone (Fig. 6D).

3.9. Infection of HuS-E7/DN24 cells with different HCV genotypes

Huh7.5 and HuS-E7/DN24 cells were separately infected with serums derived from 3 different HCV-patients or by JFH-1 concentrated medium (HCV-2a). Two serums were infected by HCV-1b, while the third by HCV-2b. Inoculated virus titer was adjusted to be the same in all cases. Except for JFH-1, which efficiently



Fig. 6. (A) The pLXSH-HA-DNIRF-7 plasmid was transfected into HuS-E/2 cells, followed by selection in 100 μg/ml Hygromycin B. Two clones, HuS-E7/DN22 (lane 2) and HuS-E7/DN24 (lane 3), were obtained. We investigated the expression of albumin, apo-A, HNF4, and GAPDH as an internal control in parental HuS-E/2, HuS-E7/DN22, and HuS-E7/DN24 hepatocytes cultured for two weeks by RT-PCR. (B) Expression of HA-tagged DNIRF-7 (upper panel) and tubulin (control, lower panel) was detected by immunoblotting analysis. HuS-E/2 cells transiently transfected with either empty pLXSH vector (lane 1) or pLXSH-HA-DNIRF-7 (lane 2) were used as negative and positive controls, respectively, after 48 h. (C) HuS-E/2, HuS-E7/DN24, and HuS-E7/DN22 cells were transfected with IFNα-luc. HuS-E/2 cells were also cotransfected with pLXSH. All of these cells were then infected (black bar) or with Sendai virus or mock-infected, then analyzed for luciferase activity after 12 h. (D) HuS-E7/DN24 cells exhibited high infectivity to HCV samples derived from patient serum. HuS-E/2 cells were transiently transfected with empty pLXSH. Twenty-four hours later, serum from a recurrently transplanted HCV patient was used to infect transfected cells and HuS-E7/DN22 and HuS-E7/DN24 cells for 24 h. After washing three times, cells were cultured in fresh medium. Cells were then harvested and lysed at the indicated time points.



Fig. 7. The infectability of Huh-7.5 and HuS-E7/DN24 cells to different HCV genotypes. Huh-7.5 (A) and HuS-E7/DN24 (B) cells were infected with same titer of JFH1 (HCV-2a), two different HCV-1b serums and one HCV-2b serum. After removing the infected medium, the cells were washed in PBS and recultured in fresh medium. Cells were harvested and lysed at the indicated time points. The quantity of HCV genome RNA per 500 ng RNA was detected by real-time RT-PCR analysis.

replicated in Huh7.5 cells (Fig. 7A), HuS-E7/DN24 cells showed a higher and reproducible infectability for the different HCV strains than Huh7.5 cells (Fig. 7B). Similar higher infectability of HuS-E7/DN24 cells was observed with HCV-4a genotype (unpublished data). These results suggest that the high infectability of Huh-7.5 with JFH-1 is specific among the combinations of HCV strains and cell lines; while HuS-E7/DN24 cells were generally permissive to HCV-infected serum independent of HCV strains.

4. Discussion

This study demonstrates that ectopic expression of the HPV18/E6E7 genes in combination with hTERT could efficiently immortalize mature human hepatocytes, generating a cell line with stable expression of hepatocyte markers and functions for more than 30 weeks in culture. HuS-E/2 cells continuously exhibited higher expression of both HGF and HGFR than HuS-T/2 cells. This result suggests that HPV18/E6E7-immortalized hepatocytes maintain responsiveness to paracrine signals capable of inducing cell differentiation to a greater extent than SV40 T-immortalized hepatocytes. This conclusion is further supported by the increased expression of HNF4 in HuS-E/2 cells in comparison to HuS-T/2 cells. HNF4 is a major hepatocyte transcription factor, required for hepatocyte differentiation and liver-specific gene expression [26]. HNF4 drives hepatocytes differentiation by acting upstream in a transcription factor cascade that included HNF1α [27]. HuS-E/2 cells continued to express HNF1α throughout prolonged culture, while HuS-T/2 cells lost expression completely. Maintenance of hepatocellular functions was demonstrated by continuous and high expression of albumin, apolipoprotein-A, human transferrin, and E-cadherin by HuS-E/2 in comparison to HuS-T/2 cells. These differences became more pronounced in the late passages. In a similar manner, HuS-E/2 cells continued to express all of the examined CYP genes, with the exception of CYP 3A4, while HuS-T/2 cells lost expression of CYP 3A4, 1B, and 2E1 completely and displayed markedly lower expression of CYP 1B1 than HuS-E/2 cells. Thus, human hepatocytes immortalized by HPV E6/E7 transfection are phenotypically similar to primary hepatocytes, even during extended cultures.

Recently, it was reported that the JFH-1 strain and derived chimeras could only infect and propagate efficiently in Huh7.5.1 and Huh7.5 cells, both of which are subclones of Huh7 cells [7–9]. This limitation, however, may be specific to the JFH-1 strain, which may not accurately reflect the course of other HCV strains' infection. Thus, usage of HCV particles isolated from patient serum could be more useful to study authentic HCV infection. Using sera from HCV patients as a source of infective virus, HPV18/E6E7-immortalized cell lines exhibited higher reproducible susceptibility to HCV infection than HuS-T, PH5CH8, and Huh-7.5 cell lines.

IRF3 and IRF7 play an important role in the activation of interferon signaling [28]. We suppressed the functions of IRF-3 or IRF-7 to assess their role in HCV infectivity. In fact, we observed significant increase of HCV replication in HuS-E/2 cells bearing dominant-negative IRF7 that impaired IFN signaling. The suppression of IRF-3, however, did not have any significant effect on HCV infectivity or replication in this cell line. This may result from the blockade of IRF-3 activation by an HCV NS3/4A serine protease [29] through at least two independent pathways that inhibit the TLR3-dependent and RIG-I-dependent signaling pathways [29–33]. Although HCV was shown to inhibit basal expression levels of IRF-7 at both mRNA and protein levels and it was shown that NS5A suppresses IRF-7-induced IFNα promoter activation [34], Stimulation of TLR7 was shown to activate IRF-7 and induce suppression of HCV replicon levels in Huh-7 cells [35]. This suggests that the inhibition of IRF7 by HCV is not complete. Using IRF-7-deficient (IRF-7−/−) mice, Honda [36] demonstrated that the transcription factor IRF-7 is essential for the induction of IFNα/β genes. We established a clone stably expressing DNIRF-7 (HuS-7E/DN24), which demonstrated higher infectivity with different HCV strains than the parental HuS-E/2 clone.

In summary, we have established a human hepatocyte-derived cell line that maintains the characteristic features of primary hepatocytes by transduction with HPV18/E6E7. This cell line is highly infectable by HCV, which suggests that these cells may be useful to characterize the molecular mechanisms involved with HCV infection and to develop novel HCV treatment modalities.

Acknowledgements

We thank Dr. Akagi at Osaka Bioscience Institute for providing hTERT expressing vector, Dr. Sakai at the Institute for Virus Research, Kyoto University, for providing HPV18/E6E7 expressing plasmid, and Dr. Taniguchi of the University of Tokyo for providing IFNβ, and IFNα promoters' reporter plasmids. This work was supported by Grants-in-Aid for cancer research and for the second-term comprehensive 10-year strategies for cancer control from the Ministry of Health, Labor and Welfare, by Grants-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, by Grants-in-Aid for the research for the future program from the Japanese society for the Promotion of Science. Dr. Hussein H. Aly is a receiver of the Japanese *Gakushu Shoreihi* scholarship and was partly supported by Prof. *Yassin A. El Ghaffar memorial scholarship* for the Improvement of Liver research in Egypt.

References

[1] Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1–16.

[2] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.

[3] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975–982.

[4] Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355.

[5] Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265–2271.

[6] Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288–292.

[7] Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791–796.

[8] Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294–9299.

[9] Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623–626.

[10] Dellgado JP, Parouchev A, Allain JE, Pennarun G, Gauthier LR, Dutrillaux AM, et al. Long-term controlled immortalization of a primate hepatic progenitor cell line after Simian virus 40 T-Antigen gene transfer. Oncogene 2005;24:541–551.

[11] Mizuguchi T, Mitaka T, Katsuramaki T, Hirata K. Hepatocyte transplantation for total liver repopulation. J Hepatobiliary Pancreat Surg 2005;12:378–385.

[12] Isom HC, Tevethia MJ, Kreider JW. Tumorigenicity of simian virus 40-transformed rat hepatocytes. Cancer Res 1981;41: 2126–2134.

[13] Ray FA, Waltman MJ, Lehman JM, Little JB, Nickoloff JA, Kraemer PM. Identification of SV40 T-antigen mutants that alter T-antigen-induced chromosome damage in human fibroblasts. Cytometry 1998;31:242–250.

[14] Chen WH, Lai WF, Deng WP, Yang WK, Lo WC, Wu CC, et al. Tissue engineered cartilage using human articular chondrocytes immortalized by HPV-16 E6 and E7 genes. J Biomed Mater Res A 2006;76:512–520.

[15] Dimri G, Band H, Band V. Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res 2005;7:171–179.

[16] Harms W, Rothamel T, Miller K, Harste G, Grassmann M, Heim A. Characterization of human myocardial fibroblasts immortalized by HPV16 E6–E7 genes. Exp Cell Res 2001;268:252–261.

[17] Shiga T, Shirasawa H, Shimizu K, Dezawa M, Masuda Y, Simizu B. Normal human fibroblasts immortalized by introduction of human papillomavirus type 16 (HPV-16) E6-E7 genes. Microbiol Immunol 1997;41:313–319.

[18] Akimov SS, Ramezani A, Hawley TS, Hawley RG. Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells. Stem Cells 2005;23:1423–1433.

[19] Hung SC, Yang DM, Chang CF, Lin RJ, Wang JS, Low-Tone Ho L, et al. Immortalization without neoplastic transformation of human mesenchymal stem cells by transduction with HPV16 E6E7 genes. Int J Cancer 2004;110:313–319.

[20] Wang G, Johnson GA, Spencer TE, Bazer FW. Isolation, immortalization, and initial characterization of uterine cell lines: an in vitro model system for the porcine uterus. In vitro Cell Dev Biol Anim 2000;36:650–656.

[21] Hino H, Tateno C, Sato H, Yamasaki C, Katayama S, Kohashi T, et al. A long-term culture of human hepatocytes which show a high growth potential and express their differentiated phenotypes. Biochem Biophys Res Commun 1999;256:184–191.

[22] Watashi K, Hijikata M, Hošaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282–1288.

[23] Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M, et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology 2005;331:407–417.

[24] Dasgupta A, Hughey R, Lancin P, Larue L, Moghe PV. E-cadherin synergistically induces hepatospecific phenotype and maturation of embryonic stem cells in conjunction with hepatotrophic factors. Biotechnol Bioeng 2005;92:257–266.

[25] Civas A, Island ML, Genin P, Morin P, Navarro S. Regulation of virus-induced interferon-A genes. Biochimie 2002;84:643–654.

[26] Ishiyama T, Kano J, Minami Y, Iijima T, Morishita Y, Noguchi M. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci 2003;94:757–763.

[27] Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003;124: 432–444.

[28] Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, et al. Interferon regulatory factors: the next generation. Gene 1999;237:1–14.

[29] Foy E, Li K, Wang C, Sumpter Jr R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145–1148.

[30] Sumpter Jr R, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79:2689–2699.

[31] Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 2005;79:3969–3978.

[32] Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102:2992–2997.

[33] Foy E, Li K, Sumpter Jr R, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005;102:2986–2991.

[34] Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005;42:819–827.

[35] Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006;103:1828–1833.

[36] Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772–777.

Available online at www.sciencedirect.com
ScienceDirect
Biochemical and Biophysical Research Communications 352 (2007) 170–176
BBRC
www.elsevier.com/locate/ybbrc

Helper virus-independent *trans*-replication of hepatitis C virus-derived minigenome

Jing Zhang [a,*], Osamu Yamada [a], Hiroshi Yoshida [a], Takashi Sakamoto [a], Hiromasa Araki [a], Kunitada Shimotohno [b]

[a] *Research and Development Center, FUSO Pharmaceutical Industries, LTD., 2-3-30 Morinomiya, Joto-ku, Osaka 536-8523, Japan*
[b] *Department of Viral Oncology, The Institute for Virus Research, Kyoto University, Kyoto 606-8397, Japan*

Received 25 October 2006
Available online 13 November 2006

Abstract

We have previously described a synthetic T7-driven cDNA minigenome containing the antisense sequence of luciferase gene and internal ribosome entry site of encephalomyocarditis virus flanked by 5′- and 3′-end sequences of hepatitis C virus (HCV) that contain *cis*-acting replication elements. Synthesis of minus-strand RNA from the artificial minigenome was determined by using Huh-7 cells harboring autonomously replicating HCV subgenome as a helper for provision of functional replication components. To further confirm and extend these studies, we investigated here whether the minigenome replication system could be reconstituted by transfection of naïve Huh-7 cells with plasmid expressing nonstructural (NS) proteins. Reporter assay and Northern blot analysis revealed that *trans*-expression of NS proteins from 3 to 5 resulted in high level of luciferase activity and synthesized minus-strand RNA. The analogous result was also obtained with the minigenome derived from HCV 2a, and both HCV 1b- and 2a-derived NS protein were able to support the chimeric minigenomes whose 5′- or 3′-end was replaced by the respective region of the heterologous virus. These results provide a basis for establishing the reverse genetic system that is helpful to study *cis*- and *trans*-acting factors involved in HCV RNA replication.

Keywords: Hepatitis C virus; Minigenome; *trans*-Replication

Hepatitis C virus (HCV) is an important human pathogen with an estimated 170 million chronic carriers throughout the world, and many of them are at a high risk for developing liver cirrhosis and hepatocellular carcinoma [1]. HCV is a member of the *Flaviviridae* family with a positive-sense RNA genome of ~9600 nucleotides in length. The genome is flanked by highly structured nontranslated regions (NTRs) important for both RNA translation and replication. The viral genome encodes a polyprotein precursor of approximately 3010 amino acids, which is processed by viral and cellular protease to produce the structural proteins (core, E1, and E2) and nonstructural (NS) proteins (p7 and NS2 to NS5B).

Like other plus-stranded RNA viruses, HCV genomic RNA is first transcribed into a minus-strand intermediate, which in turn serves as the template for production of progeny plus-strand RNA. Although the basic steps in replication have been well established, little is known about the detail of these processes. Studies of HCV replication have been hampered by the lack of an efficient tissue culture system. Although the development of subgenomic replicon has facilitated the investigation of viral RNA replication in cell culture [2], culture-adaptive mutations within the NS proteins are required for efficient replication [3,4], and full-length genomes carrying such mutations do not produce infectious virus particles [5,6]. More recently, it was reported that genotype 2a JFH1 genome replicates efficiently independent of the culture-adaptive mutations and supports production of viral particles [7]. This *in vitro* system, together with the later-developed JFH1-based

* Corresponding author. Fax: +81 6 6964 2706.
E-mail address: j-zhang@fuso-pharm.co.jp (J. Zhang).

0006-291X/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2006.10.188

chimeras [8,9], are an important progress in HCV research, allowing the study of unknown aspects of HCV life cycle. However, a comparison study showed that JFH1 differs from the earlier-generated HCV 1b replicon in independence of the cellular cofactor (cyclophilin B) for the replication and less sensitivity to antiviral reagent [10], suggesting that the strain- or genotype-specific properties may exist and the observation obtained with JFH1 cannot be simply extrapolated to other isolates.

Synthetic minigenomes have been described in a number of minus- and plus-stranded RNA viruses, which has contributed greatly to the analysis of *cis*-acting sequences and *trans*-acting proteins required for viral replication, maturation, and packaging [11,12]. We previously established a helper virus-dependent expression system utilizing HCV-derived minigenome, and Huh-7 cells harboring autonomously replicating HCV subgenome [13]. In this study, we further investigated whether the minigenome replication system could be reconstituted by transfection of naïve Huh-7 cells with plasmid expressing NS proteins. It was shown that synthesis of minus-strand RNA from HCV minigenome can be supported by *trans*-expressed polyprotein NS3 to NS5B, and the NS proteins were able to replicate not only the homologous minigenome but the heterologous and chimeric minigenome as well.

Materials and methods

Plasmids. HCV 1b-derived minigenome p1b-1b was previously referred to as pT7cRLNS5B1 [13]. For construction of chimeric minigenome p2a-1b, the first 376 nucelotides of HCV 2a cDNA with the T7 promoter directly coupled at the 5′-end were amplified by PCR with primers 5′-tataa gcttTAATACGACTCACTATAACCTGCCCCTAATAGGGGC-3′ and 5′-tgcgcatgcTTTGGTTTTTCTTTGAGGTT-3′. The *Renilla* luciferase gene was amplified from pRL-TK (Promega) using primers 5′-ctctctagaA TGACTTCGAAAGTTTATGA-3′ and 5′- tgcgcatgcTTATTGTTCATT TTTGAGAA-3′. The resulting PCR products were digested with *Hin*dIII–*Sph*I and *Sph*I–*Xba*I, respectively, and inserted into the *Hin*dIII/*Xba*I sites of p1b-1b. The 3′- part of the NS5B coding region fused 3′ UTR of HCV 2a cDNA was amplified by PCR using primers 5′-ataggatccCCTCAGAA AACTTGGGG-3′ and 5′-ataggcgccagcgaggaggctgggaccatgccggccACAT GATCTGCAGAGAGACC-3′, digested with *Bam*HI and *Nar*I, and cloned, along with the annealed oligonucleotides containing partial sequence of the HDV ribozyme [13], into *Bam*HI/*Eco*RI-cut p1b-1b or p2a-1b, creating p1b-2a and p2a-2a, respectively.

To construct plasmid pNS3-51b expressing polyprotein from HCV 1b, a cDNA containing the ORF of NS3 to NS5B was amplified with primers 5′-atatctagaATGGGCCCATCACGGCTTA-3′ and 5′-ataggcgcgccTCA CCGGTTGGGGAGCAGG-3′, digested with *Xba*I and *Asc*I, and cloned, along with *Hin*dIII/*Xba*I-cut HCV sequence (1–341 nt), into pGEMEX-1 vector (Promega) which was modified by deletion of all of the T7 gene 10 and introduction of *Hin*dIII and *Asc*I sites between T7 promoter and terminator [14]. pNS3-52a, which expresses the polyprotein from HCV 2a, was constructed similarly except with the primers of corresponding sequence from genotype 2a. The sequences of these constructs were confirmed by nucleotide sequencing.

Cells. The cell line Huh-7 was purchased from the American Type Culture Collection (ATCC) and maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum and 50 U/ml penicillin and streptomycin in a 5% CO_2 humidified atmosphere. A Huh-7-derived cell line (Huh–NNRZ) stably replicating HCV subgenomic replicon was grown in DMEM containing 300 μg/ml G418 (Geneticin, Invitrogen) [15,16].

Transfection. Huh-7 cells were seeded at 1×10^5 per well of 12-well plates. Twenty-four hours later, 0.5 μg *Eco*RI-linearized minigenome (p1b-1b, p1b-2a, p2a-1b, or p2a-2a), 0.5 μg pGEMEX-1, pNS3-51b, or pNS3-52a, 0.5 μg pAM8-1, and 0.1 μg pGL3-Control vector were cotransfected into cells with Fugene HD Transfection Reagent (Roche). The cells were harvested at the indicated time points, and cell lysates were assayed for luciferase activity as described below.

Luciferase assay. Cell lysates were prepared from transfected cells, centrifuged briefly, and 20 μl of the supernatants was used for luciferase assays with Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Luciferase activities were measured using a TD-20/20 Luminometer (Promega).

Western blot analysis. Protein was electrophoresed on a sodium dodecyl sulfate–polyacrylamide gel, transferred to Hybond-P PVDV Membrane (Amersham). The blots were probed with Antiserum Product 2871 and 2881 (ViroStat) for detection of NS3 and NS4, rabbit polyclonal antibody (ab2594, Abcam Limited) for NS5A, and goat polyclonal antibody (sc-17532, Santa Cruz Biotechnology, Inc.) for NS5B. Signals were visualized with ECL Plus Western Blotting Detection Reagents (Amersham).

Northern blot analysis. RNAs were isolated from transfected cells with Trizol reagent (Invitrogen) and treated with RNase-free DNase (Promega). The purified RNAs were separated by denaturing agarose gel electrophoresis and analyzed by Northern blot using digoxigenin-labeled antisense *Renilla* luciferase sequence.

Results

Synthetic minigenome derived from HCV

The minigenome construct derived from HCV 1b consists of the antisense sequence of the *Renilla* luciferase gene and internal ribosome entry site (IRES) of encephalomyocarditis virus (EMCV) flanked upstream by 5′-end (nucleotides 1–377) and downstream by 3′-end sequence containing NS5B coding region from nucleotides 9067 to 9371 plus 3′-UTR of HCV cDNA. The cassette was positioned precisely at the T7 transcription start site followed by self-cleaving HDV ribozyme to ensure authentic 5′- and 3′-ends (Fig. 1A, p1b-1b). If the minigenome could be accepted as a template by the replication complex provided in *trans*, the luciferase gene, which is encoded by synthesized minus-strand RNA, would express in HCV-infected cells. Fully consistent with this hypothesis, luciferase activity was selectively detected in Huh-7 cells harboring an autonomously replicating HCV subgenome (Huh–NNRZ) [13].

Replication of HCV minigenome in Huh-7 cells expressing polyprotein NS3 to NS5B

The ability of the synthetic minigenome to replicate in replicon cells prompted us to investigate whether the replication of minigenome could be supported by HCV proteins expressed in *trans*. For this purpose, Huh-7 cells were transfected with the minigenomic construct p1b-1b, plasmid encoding a polyprotein encompassing NS3 to NS5B under the control of T7 RNA polymerase promoter, pAM8-1 plasmid expressing T7 RNA polymerase [14], and pGL3-Control vector. The cells were harvested at 3



Fig. 1. Schematic diagrams of T7-based minigenomes derived from HCV 1b (A), HCV 2a (B), chimeric minigenomes p1b-2a consisting of 5′-end of HCV 1b and 3′-end of HCV 2a (E) and p2a-1b consisting of 5′-end of HCV 2a and 3′-end of HCV 1b (F). HCV minigenome containing the antisense sequence of the *Renilla* luciferase gene and EMCV IRES flanked by the 5′-end and 3′-partial NS5B coding sequence-connected 3′-UTR was juxtaposed precisely at the T7 transcription start site and followed by the HDV ribozyme sequence. pnu-1b (C) and pnu-2a (D) were identical to p1b-1b and p2a-2a except for the 5′-end sequences deleted.

days posttransfection, protein expression was verified by Western blot analysis (Fig. 2) and the replication of minigenome was determined by luciferase assay and Northern blot analysis. The firefly luciferase activity from cotransfected pGL3-Control vector was simultaneously measured to normalize the transfection efficiency. As shown in Fig. 3A, only background level of *Renilla* luciferase (Rluc) activity was detected in cells transfected with the empty vector. Cotransfection of the plasmid encoding the polyprotein NS3 to NS5B (pNS3-51b) resulted in significant *Renilla* luciferase expression. Omission of pAM8-1 in the transfection mixture completely abrogated *Renilla* luciferase activity, largely ruling out the possibility that the minus-strand RNA used here as the mRNA for reporter gene expression was synthesized as a consequence of the transcription by a cryptic promoter. Consistent with the results reported previously [13], *Renilla* luciferase activity was also detected in Huh–NNRZ cells stably replicating the HCV subgenomic replicon, although it was lower than that in cells *trans*-expressing the polyprotein. The fact that the replicase complex reconstituted by *trans*-expressed polyprotein could support more efficient replication of the minigenome may be attributable to the higher expression level of plasmid-encoded protein on a per-transfected-cell basis. Alternatively, the recruitment of the replication complex to the minigenome may be competed by the subgenomic replicon, because both of these share the replication machinery in replicon cells.

To further confirm the result of reporter assay, RNA was extracted from transfected cells and subjected to Northern blot analysis using digoxigenin-labeled antisense *Renilla* luciferase probes. Also, minus-strand RNA transcripts of the expected size were specifically detected in Huh-7 cells expressing NS 3–5 protein and Huh–NNRZ cells replicating HCV subgenomic replicon (Fig. 3B, lanes 2 and 4). These data demonstrate that *trans*-replication of HCV minigenome does not require replication of the helper viral RNA.



Fig. 2. Expression of NS proteins in Huh-7 cells transfected with plasmid encoding a polyprotein encompassing NS3 to NS5B. Huh-7 cells were transfected with pNS3-51b together with pAM8-1 plasmid expressing T7 RNA polymerase and harvested at day 3 posttransfection. Cell lysates of the transfected cells were analyzed by Western blot using antibodies against each NS protein. Protein standard is shown on the right, and the band corresponding to each NS protein is indicated by an arrowhead. Huh-7 cells transfected with the empty vector served as a negative control (NC).

To document that the reporter gene expression detected above was dependent on HCV replicase reconstituted by *trans*-expressed NS proteins, we employed inactive mutant pNS3-51b/dGDD (in which the GDD motif of NS5B was deleted) and AdsiNS5B expressing siRNA directed against NS5B [13] in the reporter assay. As shown in Fig. 3C, the deletion of GDD motif significantly attenuated the ability of NS proteins to support minigenome replication, and transduction with AdsiNS5B resulted in a substantial and dose-dependent reduction in luciferase expression. These results provide further evidence that the reporter gene was expressed as a result of replication of HCV minigenome by *trans*-supplied NS proteins.

Chimeric minigenomes as templates for HCV replication complex

Next, we were interested in investigating whether the replicase of HCV can recognize the heterologous signals for synthesis of minus-strand RNA. For this purpose, HCV minigenome from distantly related genotype 2a (Fig. 1B, p2a-2a), minigenomes with 5′-end deleted (Fig. 1C and D, pnu-1b and pnu-2a), and chimeric minigenomes whose 5′- or 3′-end was replaced by the respective region of the heterologous virus (Fig. 1E and F, p1b-2a and p2a-1b) were constructed. Huh-7 cells were transfected with these minigenomes together with the plasmid expressing HCV 1b- or 2a-derived NS proteins, pAM8-1, and *Renilla* luciferase activities were measured as fore-mentioned. Consistent with the results described above, replicase of HCV 1b and 2a accepted its respective minigenome as the template for synthesis of minus-strand RNA, and exchange of NS proteins between HCV1b- and 2a-derived minigenome systems also led to reporter gene expression (Fig. 4), implying that the replication complex is not strictly specific for the homologous RNA template. Deletion of the 5′-end region in the minigenome fully abrogated its replication, both NS proteins from HCV 1b and 2a, however, could support the replication of chimeric minigenomes, suggesting that both RNA–protein interaction between replicase and viral genome and long range RNA–RNA interaction between 5′- and 3′-terminal sequence involved in HCV minus-strand RNA synthesis are functionally conserved between genotype 1b and 2a. Additionally, in all tested minigenomes, the NS proteins originated from HCV 1b constantly yielded higher levels of luciferase expression than that from 2a, suggesting that intrinsic differences in the replication capabilities of the replicase complex from different strains may exist. More likely, the superior capability of pNS3-51b in supporting the minigenomes replication may be attributable to the fact that the coding sequence in pNS3-51b was amplified from the replicon which harbors the adaptive mutations due to long-term culture, whereas the coding region in pNS3-52a was directly amplified from HCV 2a-infected serum.

Discussion

Successful establishment of the minigenome system has been described in a number of minus-stranded RNA viruses from different families and plus-stranded RNA viruses belonging to the *Coronaviridae* family, which has contributed greatly to the analysis of *cis*-acting sequences and *trans*-acting proteins essential for viral replication [11,12]. The rescue of synthetic minigenomes was achieved either through helper virus infection of minigenome-transfected



Fig. 3. Replication of HCV minigenome in Huh-7 cells expressing polyprotein NS3 to NS5B. (A) Huh-7 or Huh–NNRZ cells were transfected with p1b-1b, pNS3-51b expressing polyprotein NS3 to NS5B, together with or without pAM8-1. Relative *Renilla* luciferase activities in the lysates were determined at 72 h posttransfection. The columns and bars represent mean and standard deviation of four independent experiments. (B) Northern blot was performed on 8 μg of extracted RNA using digoxigenin-labeled antisense *Renilla* luciferase RNA probe to detect minus-strand transcripts. RNA size markers are shown on the left, and the bands corresponding to minus-strand RNA are indicated on the right. (C) Huh-7 cells were transfected with p1b-1b, pAM8-1, and pempty, pNS3-51b or pNS3-51b/dGDD (column 1–3), or infected with AdsiNS5B at an MOI of 100, 50, and 20 (column 4–6) before transfection, and relative *Renilla* luciferase activities in the lysates were determined as described above.

cells with virus particles or through co-transfection of plasmids expressing viral proteins. For viruses of *Flaviviridae* family, however, a little has been reported in the development of similar approach except an *in vitro* replication system which utilizes cytoplasmic extracts from viral-infected cells and exogenous RNA template containing 5′- and 3′-terminal regions was described for dengue virus [17]. Together with those reported previously [13], the data shown here represent the first example of minigenome system for HCV, indicating that both the replicase complex supplied from replicating subgenomic replicon and that reconstituted by plasmid-encoded NS proteins are capable of supporting the replication of HCV minigenome.

The data shown here further confirm that the viral 5′- and 3′-end sequence together with the 3′-partial NS5B coding region represent sufficient *cis*-acting signals for minus-strand RNA synthesis. These results, however, do not rule out the possibility for the existence of *cis*-acting elements in other coding region, which may act as regulatory elements (either enhancers or silencers) in RNA synthesis. The presence of noncontiguous *cis*-acting signals involved in viral RNA replication has been reported in the viral genome of the brome mosaic virus [18], tobacco mosaic virus [19], and the double-stranded RNA virus of yeast [20].

Similar to that found in dengue virus, it was shown that deletion of the 5′-end region in the minigenome fully abrogated its replication, but substitution of the 5′-end with the respective sequence from heterologous virus (p1b-2a or p2a-1b) did not significantly affect its template ability, suggesting that the long range RNA–RNA interaction between 5′- and 3′-ends essential for RNA replication is functionally conserved between HCV 1b and 2a. In addition to homologous minigenome, both HCV 1b- and 2a-derived replicase were able to accept the heterologous and chimeric minigenomes as the templates for synthesis of minus-strand



Fig. 4. Replication of chimeric HCV minigenomes. Huh-7 cells were transfected with each indicated minigenome, pAM8-1, and pNS3-51b or pNS3-52a expressing polyprotein NS3 to NS5B derived from genotype 1b or 2a. Relative *Renilla* luciferase activities in the lysates were determined as described for Fig. 3A. The columns and bars represent means and standard deviations of three independent transfections.

RNA, indicating that the replicase-catalyzed RNA synthesis is not strictly strain- or genotype-specific.

Using replicon system, Bartenschlager's group obtained the evidence showing that only mutations in NS5A, but not mutations in NS3, NS4B, and NS5B, could be rescued by *trans*-complementation [21]. Our data presented here indicate that replication of the minigenome can be supported by *trans*-expressed NS proteins. One scenario may make these two different findings compatible: the *cis*-expressed, lethally mutated NS proteins may exert dominant negative effect in reconstituting replication complex, and thus interfere with the incorporation of *trans*-supplied NS proteins into a functional replication complex, which may account for the failure of NS proteins (other than NS5A) to *trans*-complement HCV RNA replication; however, such a dominant negative effect does not exist in the minigenome system described here because there is no NS protein expressed in *cis*, and *trans*-expressed NS proteins might be able to reconstitute the functional replication complex to support minigenome replication. Further experiments are now in progress to substantiate this assumption.

It is generally believed that the HCV replication follows the pathway used by other plus-strand RNA viruses: the input RNA is first transcribed into a minus strand, which in turn serves as the template for production of progeny plus strand. The negative strand intermediates are postulated to exist as a dsRNA form. However, there is no direct evidence demonstrating this postulation in HCV, and whether there is free HCV-specific RNA of negative polarity in infected cells is still an issue to be elucidated. On the other hand, increasing evidence showed that the RNA in native replication intermediates of some positive strand RNA viruses is single-stranded. For example, in polio virus-infected cells, a careful electron microscope analysis using a membrane-permeable cross-linking reagent demonstrated that the native replication intermediate *in vivo* has a predominantly single-stranded backbone attached to several nascent RNA chains with few or no regions of extensive base-pairing, although deproteined (phenol-extracted) replication intermediate has a backbone mostly double-stranded [22]. More recently, Fujimura et al., reported that native replication intermediates of 20 S RNA virus have a single-stranded RNA backbone [23]. After completion of product-strand elongation, both the product and template strands are released from the replication complex as single-stranded RNA. The data presented here indicate that the minus strand RNA could serve as the mRNA for transgene expression, implying a similar scenario may also occur in HCV replication and minus strand RNA may be dissociated and present as a free single-strand form after RNA synthesis is completed.

One issue of concern in using minigenome to study the molecular mechanism of viral replication is whether the elements controlling viral replication in the context of minigenome could authentically reflect those that occurred in the context of full-length genome. Recently, differential effect of a point mutation in the replicase gene on genome and minigenome replication was reported in coronavirus, emphasizing the need to use full-length genome to validate the replication signals obtained from minigenome system [24]. Nonetheless, the HCV minigenome system described here represents a useful tool for identification of *cis*- and *trans*-acting factors involved in viral replication while eliminating biosafety constraints required for work with infectious systems. Additionally, it will be of interest to explore whether the HCV minigenome can be packaged by additional provision of the viral structural protein in *trans*, and its success will not only further broaden the

application of the HCV minigenome, but also facilitate the development of HCV-based gene delivery system.

We describe here a reverse genetic system for HCV that is based on T7-driven minigenome coupled with plasmid-encoded NS proteins. This system opens the possibility of manipulation of *cis*-acting signals and *trans*-acting factors involved in the control of HCV RNA synthesis, which may facilitate future studies aimed at investigation of the mechanisms involved in the replication of viral RNA.

References

[1] M.J. Alter, Epidemiology of hepatitis C, Hepatology 26 (1997) 62S–65S.

[2] V. Lohmann, F. Korner, J.O. Koch, U. Herian, L. Theilmann, R. Bartenschlager, Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line, Science 285 (1999) 110–113.

[3] K.J. Blight, A.A. Kolykhalov, C.M. Rice, Efficient initiation of HCV RNA replication in cell culture, Science 290 (2000) 1972–1974.

[4] N. Krieger, V. Lohmann, R. Bartenschlager, Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations, J. Virol. 75 (2001) 4614–4624.

[5] J. Bukh, T. Pietschmann, V. Lohmann, N. Krieger, K. Faulk, R.E. Engle, S. Govindarajan, M. Shapiro, M. St Claire, R. Bartenschlager, Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees, Proc. Natl. Acad. Sci. USA 99 (2002) 14416–14421.

[6] T. Pietschmann, V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand, R. Bartenschlager, Persistent and transient replication of full-length hepatitis C virus genomes in cell culture, J. Virol. 76 (2002) 4008–4021.

[7] T. Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.G. Krausslich, M. Mizokami, R. Bartenschlager, T.J. Liang, Production of infectious hepatitis C virus in tissue culture from a cloned viral genome, Nat. Med. 11 (2005) 791–796.

[8] B.D. Lindenbach, M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, T. Maruyama, R.O. Hynes, D.R. Burton, J.A. McKeating, C.M. Rice, Complete replication of hepatitis C virus in cell culture, Science 309 (2005) 623–626.

[9] T. Pietschmann, A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F.L. Cosset, R. Bartenschlager, Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras, Proc. Natl. Acad. Sci. USA 103 (2006) 7408–7413.

[10] N. Ishii, K. Watashi, T. Hishiki, K. Goto, D. Inoue, M. Hijikata, T. Wakita, N. Kato, K. Shimotohno, Diverse effects of cyclosporine on hepatitis C virus strain replication, J. Virol. 80 (2006) 4510–4520.

[11] A. Izeta, C. Smerdou, S. Alonso, Z. Penzes, A. Mendez, J. Plana-Duran, L. Enjuanes, Replication and packaging of transmissible gastroenteritis coronavirus-derived synthetic minigenomes, J. Virol. 73 (1999) 1535–1545.

[12] M. Perez, A. Sanchez, B. Cubitt, D. Rosario, J.C. de la Torre, A reverse genetic system for Borna disease virus, J. Gen. Virol. 84 (2003) 3099–3104.

[13] J. Zhang, O. Yamada, T. Sakamoto, H. Yoshida, H. Araki, K. Shimotohno, Exploiting *cis*-acting replication elements to direct hepatitis C virus-dependent transgene expression, J. Virol. 79 (2005) 5923–5932.

[14] J. Zhang, O. Yamada, T. Ito, M. Akiyama, Y. Hashimoto, H. Yoshida, R. Makino, A. Masago, H. Uemura, H. Araki, A single nucleotide insertion in the 5′-untranslated region of hepatitis C virus leads to enhanced cap-independent translation, Virology 261 (1999) 263–270.

[15] H. Kishine, K. Sugiyama, M. Hijikata, N. Kato, H. Takahashi, T. Noshi, Y. Nio, M. Hosaka, Y. Miyanari, K. Shimotohno, Subgenomic replicon derived from a cell line infected with the hepatitis C virus, Biochem. Biophys. Res. Commun. 293 (2002) 993–999.

[16] J. Zhang, O. Yamada, T. Sakamoto, H. Yoshida, T. Iwai, Y. Matsushita, H. Shimamura, H. Araki, K. Shimotohno, Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus, Virology 320 (2004) 135–143.

[17] S. You, R. Padmanabhan, A novel in vitro replication system for Dengue virus, J. Biol. Chem. 274 (1999) 33714–33722.

[18] F.C. Lahser, L.E. Marsh, T.C. Hall, Contributions of the brome mosaic virus RNA-3 3′-nontranslated region to replication and translation, J. Virol. 67 (1993) 3295–3303.

[19] V. Leathers, R. Tanguay, M. Kobayashi, D.R. Gallie, A phylogenetically conserved sequence within viral 3′ untranslated RNA pseudoknots regulates translation, Mol. Cell. Biol. 13 (1993) 5331–5347.

[20] R. Esteban, T. Fujimura, R.B. Wickner, Internal and terminal *cis*-acting sites are necessary for in vitro replication of the L-A double-stranded RNA virus of yeast, EMBO J. 8 (1989) 947–954.

[21] N. Appel, U. Herian, R. Bartenschlager, Efficient rescue of hepatitis C virus RNA replication by *trans*-complementation with nonstructural protein 5A, J. Virol. 79 (2005) 896–909.

[22] O.C. Richards, S.C. Martin, H.G. Jense, E. Ehrenfeld, Structure of poliovirus replicative intermediate RNA. Electron microscope analysis of RNA cross-linked in vivo with psoralen derivative, J. Mol. Biol. 173 (1984) 325–340.

[23] T. Fujimura, A. Solorzano, R. Esteban, Native replication intermediates of the yeast 20 S RNA virus have a single-stranded RNA backbone, J. Biol. Chem. 280 (2005) 7398–7406.

[24] C. Galan, L. Enjuanes, F. Almazan, A point mutation within the replicase gene differentially affects coronavirus genome versus minigenome replication, J. Virol. 79 (2005) 15016–15026.

Microbiol. Immunol., 51(1), 127–133, 2007

Editor-Communicated Paper

In Vitro Infection of Immortalized Primary Hepatocytes by HCV Genotype 4a and Inhibition of Virus Replication by Cyclosporin

Mohamed A. El-Farrash[1,†], Hussein H. Aly[2,3,4,†], Koichi Watashi[3], Makoto Hijikata[3], Hiroto Egawa[2], and Kunitada Shimotohno[*,3]

[1]*Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt,* [2]*Graduate School of Medicine, Department of Transplant Surgery, Kyoto University Hospital, Kyoto, Kyoto 606–8507, Japan,* [3]*Laboratory for Human Tumor Viruses, Institute for Virus Research, Kyoto University, Kyoto, Kyoto 606–8507, Japan,* [4]*Hepatology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt*

Communicated by Dr. Masanobu Ohuchi: Received November 13, 2006. Accepted November 16, 2006

Abstract: **Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide. We previously reported that cyclosporin A (CsA) inhibits HCV-1b replication. However, its inhibition of JFH-1 (HCV-2a) was much less. Since HCV genotype clearly affects the *in vitro* and *in vivo* response to anti-viral therapy, we wished to examine the effect of CsA and its non-immunosuppressive derivative NIM811 on HCV genotype 4a replication. We first established an *in vitro* system supporting HCV-4a infection and replication using immortalized human hepatocytes, HuS-E7/DN24 (HuS) cells, and these cells were infected with sera obtained from Egyptian patients with chronic HCV-4a infection. HuS cells supported more robust HCV-4a replication than both HuH-7.5 and PH5CH8 cells, and HCV-4a infection and replication were completely inhibited by 3 μg/ml CsA and 0.5 μg/ml NIM811. Thus, HuS cells are a good model system supporting the infection and high-level replication of HCV-4a, and both CsA and NIM811 effectively inhibit HCV-4a replication in this system.**

Key words: **HCV-4a, Hepatitis, NIM811, HuS**

Hepatitis C virus (HCV) is an enveloped, positive-stranded RNA virus of the genus *Hepacivirus* and family *Flaviviridae* (14). HCV is an important cause of morbidity and mortality worldwide. A high proportion of individuals infected with HCV develop chronic hepatitis, and this may progress to cirrhosis and hepatocellular carcinoma (2). The WHO estimates that there are at least 21.3 million HCV carriers in the Eastern Mediterranean countries, and this number approaches the combined estimated number of HCV carriers in the Americas (13.1 million) and Europe (8.9 million). Indeed, the prevalence of HCV infection in Egypt (15–25%) is amongst the highest in the world (18).

The genomes of a number of different HCV strains have been cloned, and the divergence of these sequences indicates the existence of at least six HCV genotypes with a number of subtypes (12). In North America and Northern Europe, HCV subtype 1a is the most common followed by 2b and 3a. In Japan, subtype 1b is responsible for up to 73% of cases of HCV infection (13). However, genotypes other than 1, 2 or 3 represent most HCV cases in the remaining countries. HCV genotype 5 has been isolated almost exclusively from patients in South Africa, and genotype 6 is primarily found in Hong Kong, Vietnam and throughout South East Asia (13). However, it is now clear that genotype 4 is largely confined to Central Africa and the Middle East, a region containing approximately one-fifth of all HCV positive individuals worldwide (10).

Address correspondence to Dr. Kunitada Shimotohno, The Institute for Virus Research, Kyoto University, 53 Kawaharacho Shogoin, Sakyo-ku, Kyoto, Kyoto 606–8507, Japan. Fax: +81–75–751–3998. E-mail: kshimoto@virus.kyoto-u.ac.jp

Abbreviations: CsA, cyclosporin A; CyPB, cyclophilin B; HCV, hepatitis C virus; HCVpp, hepatitis C virus pseudoparticles; hTERT, human telomerase reverse transcriptase; HuS, HuS-E7/DN24; IFN-α, interferon-alpha; IRF-7, interferon regulatory factor-7; MAb, monoclonal antibody; Sv40-Lt, Simian virus 40-large T antigen.